BioSpecifics Technologies, a biopharmaceutical company, has developed injectable collagenase (XIAFLEX) for 12 clinical indications. XIAFLEX is currently being marketed for the treatment of Dupuytren’s contracture and Peyronie’s disease by various companies in the U.S. and internationally. XIAFLEX is also in clinical development to treat several additional indications, and BioSpecifics is currently managing the clinical development of XIAFLEX for treating human lipoma and canine lipoma, both in Phase II clinical trials. For more information, visit the company’s Web site at www.biospecifics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: